MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and Generate:Biomedicines formed a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

We unexpectedly lost a dear friend and colleague, Dr. Cullen Taniguchi, in mid-November. Dr. Taniguchi was an exceptional and compassionate clinician, brilliant scientist, and nurturing mentor. Above all, he was a dedicated and loving husband, father, son, and brother. We deeply mourn his loss, but we forever cherish the memories and indelible legacy that he leaves with us. 

Login